JAK2V617F 会损害骨髓增殖性肿瘤中的淋巴分化

IF 8.8 1区 医学 Q1 HEMATOLOGY Leukemia Pub Date : 2024-09-07 DOI:10.1038/s41375-024-02388-3
Daniel C. Choi, Nassima Messali, Narasimha Rao Uda, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Heidi E. L. Lischer, Franco Castillo Tokumori, Katie Erdos, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao, Joseph M. Scandura
{"title":"JAK2V617F 会损害骨髓增殖性肿瘤中的淋巴分化","authors":"Daniel C. Choi, Nassima Messali, Narasimha Rao Uda, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Heidi E. L. Lischer, Franco Castillo Tokumori, Katie Erdos, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao, Joseph M. Scandura","doi":"10.1038/s41375-024-02388-3","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":18109,"journal":{"name":"Leukemia","volume":"38 11","pages":"2487-2491"},"PeriodicalIF":8.8000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms\",\"authors\":\"Daniel C. Choi, Nassima Messali, Narasimha Rao Uda, Ghaith Abu-Zeinah, Pouneh Kermani, Maria Mia Yabut, Heidi E. L. Lischer, Franco Castillo Tokumori, Katie Erdos, Thomas Lehmann, Marta Sobas, Tata Nageswara Rao, Joseph M. Scandura\",\"doi\":\"10.1038/s41375-024-02388-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":18109,\"journal\":{\"name\":\"Leukemia\",\"volume\":\"38 11\",\"pages\":\"2487-2491\"},\"PeriodicalIF\":8.8000,\"publicationDate\":\"2024-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41375-024-02388-3\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41375-024-02388-3","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

骨髓增殖性肿瘤(MPNs)源于单个造血干细胞(HSC)获得驱动突变,通常在临床表现前数十年就已发生[1]。最常见的驱动突变是JAK2V617F,它通过对骨髓造血至关重要的受体激活异常的JAK/STAT信号[2]。随着时间的推移,这种 MPN 造血干细胞克隆会取代正常的造血干细胞克隆,导致骨髓细胞过度生成。然而,淋巴细胞减少症也可见于 MPN 患者[3, 4],并导致中性粒细胞与淋巴细胞比值(NLR)升高,而 NLR 可预测疾病相关并发症,包括血栓形成和死亡率[5, 6]。为了评估 JAK2V617F 对 MPN 队列中造血的影响,我们通过荧光激活细胞分选 (FACS) 技术,用液滴数字 PCR 测量了从外周血 (PB) 中分馏出的造血亚群中的 JAK2V617F 突变等位基因频率 (MAF)。造血干细胞和多能祖细胞(造血干细胞/多能祖细胞,CD45dimCD34+CD38-CD45RA-)的MAF在MPN病程的每一年增加1.6%(±0.5%)(图1B)。尽管 JAK2V617F 在造血过程中逐渐占据主导地位,但正如之前所报道的那样,JAK2V617F 在淋巴细胞中基本不存在(图 1C 和补充图 1)[9]。因此,淋巴细胞生成不足可能会导致 JAK2V617F 多发性骨髓瘤中的淋巴细胞减少症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Leukemia
Leukemia 医学-血液学
CiteScore
18.10
自引率
3.50%
发文量
270
审稿时长
3-6 weeks
期刊介绍: Title: Leukemia Journal Overview: Publishes high-quality, peer-reviewed research Covers all aspects of research and treatment of leukemia and allied diseases Includes studies of normal hemopoiesis due to comparative relevance Topics of Interest: Oncogenes Growth factors Stem cells Leukemia genomics Cell cycle Signal transduction Molecular targets for therapy And more Content Types: Original research articles Reviews Letters Correspondence Comments elaborating on significant advances and covering topical issues
期刊最新文献
Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study. Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity. Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study. Can natural killer cells cure leukemia?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1